Payload ID	PAY0ZVLSS
Name	Pseudomonas exotoxin PE24
Synonyms	Pseudomonas exotoxin PE24    Click to Show/Hide
Target(s)	Eukaryotic elongation factor 2 (EEF2)					Target Info

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half-maximal effective concentration (EC50)	944500	nM	A431 cells	Skin squamous cell carcinoma	CVCL_0037	[1]

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 50.00% (Day 48)	Positive GPC3 expression (GPC3+++/++)
Method Description	A43-PE24 induces efficient tumor cell killing in cell line-derived models of immunotherapy of hepatocellular carcinoma cells.
In Vivo Model	Hepatocellular carcinoma CDX model
In Vitro Model	Hepatocellular carcinoma	Hepatocellular carcinoma cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	G1LG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63.30% (Day 48)	Positive GPC3 expression (GPC3+++/++)
Method Description	HN3-PE24 induces efficient tumor cell killing in cell line-derived models of immunotherapy of hepatocellular carcinoma cells.
In Vivo Model	Hepatocellular carcinoma CDX model
In Vitro Model	Hepatocellular carcinoma	Hepatocellular carcinoma cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	G1LG cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Pediatric hepatocellular carcinoma	Hep3BLG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 75.00% (Day 48)	Positive GPC3 expression (GPC3+++/++)
Method Description	C46-PE24induces efficient tumor cell killing in cell line-derived models of immunotherapy of hepatocellular carcinoma cells.
In Vivo Model	Hepatocellular carcinoma CDX model
In Vitro Model	Hepatocellular carcinoma	Hepatocellular carcinoma cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	G1LG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 78.15% (Day 6)	Positive MSLN expression (MSLN +++/++)
Method Description	In vivo efficacy of LMB-100 and LMB-164 in an SW48 mouse xenograft model was evaluated. LMB-100 was administered i.v. at 2.5 mg/kg dose every other day for 6 days for two cycles with three days in between cycles.
In Vivo Model	SW48 CDX model
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.38 ng/mL±0.08 ng/mL	Positive MSLN expression (MSLN +++/++)
Method Description	KLM-1 pancreatic adenocarcinoma cells were treated with indicated concentrations of LMB-12, LMB-100, or LMB-164 anti-MSLN targeted RITs for 72 hours before WST-8 assay of cell viability.
In Vitro Model	Pancreatic ductal adenocarcinoma	KLM-1 cells		CVCL_5146

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.30% (Day 48)	Positive GPC3 expression (GPC3+++/++)
Method Description	J80A-PE24 induces efficient tumor cell killing in cell line-derived models of immunotherapy of hepatocellular carcinoma cells.
In Vivo Model	Hepatocellular carcinoma
In Vitro Model	Hepatocellular carcinoma	Hepatocellular carcinoma cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 48)	Positive GPC3 expression (GPC3+++/++)
Method Description	J80A-PE24+FGF-401 induces efficient tumor cell killing in cell line-derived models of immunotherapy of hepatocellular carcinoma cells.
In Vivo Model	Hepatocellular carcinoma CDX model
In Vitro Model	Hepatocellular carcinoma	Hepatocellular carcinoma cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	G1LG cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.90 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Pediatric hepatocellular carcinoma	Hep3BLG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	G1LG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	G1LG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	G1LG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	G1LG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Inhibitory Concentration 5% (IC5)	110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553

Experiment 1 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	Positive PSMA expression (PSMA+++/++)
Method Description	The immunotoxins hD7-1 (VL-VH)-PE24 was tested for specific cytotoxic activity against PSMA-positive LNCaP and C4-2 cells.
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395
Experiment 2 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	Positive PSMA expression (PSMA+++/++)
Method Description	The immunotoxins hD7-1 (VL-VH)-PE24 was tested for specific cytotoxic activity against PSMA-positive LNCaP and C4-2 cells.
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Skin squamous cell carcinoma	A-431 cells		CVCL_0037
Experiment 2 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.40 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Breast ductal carcinoma	HCC70 cells		CVCL_1270
Experiment 3 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.70 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152
Experiment 4 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Breast carcinoma	SUM149PT cells		CVCL_3422
Experiment 5 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.50 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Skin squamous cell carcinoma	A-431 cells		CVCL_0037
Experiment 6 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.50 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Peritoneal malignant mesothelioma	HAY cells		CVCL_N813
Experiment 7 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	KLM-1 cells		CVCL_5146
Experiment 8 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 9 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Skin squamous cell carcinoma	A-431 cells		CVCL_0037
Experiment 10 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	.	L55S cells		Homo sapiens
Experiment 11 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.70 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	KLM-1 cells		CVCL_5146
Experiment 12 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Breast ductal carcinoma	HCC70 cells		CVCL_1270
Experiment 13 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Peritoneal malignant mesothelioma	HAY cells		CVCL_N813
Experiment 14 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 15 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	KLM-1 cells		CVCL_5146
Experiment 16 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	.	L55S cells		Homo sapiens
Experiment 17 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Skin squamous cell carcinoma	A-431 cells		CVCL_0037
Experiment 18 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Peritoneal malignant mesothelioma	HAY cells		CVCL_N813
Experiment 19 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	KLM-1 cells		CVCL_5146
Experiment 20 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Breast carcinoma	SUM149PT cells		CVCL_3422
Experiment 21 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	35.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Peritoneal malignant mesothelioma	HAY cells		CVCL_N813
Experiment 22 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	40.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 23 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	40.00 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152
Experiment 24 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 ng/mL±0.08 ng/mL	Positive MSLN expression (MSLN +++/++)
Method Description	KLM-1 pancreatic adenocarcinoma cells were treated with indicated concentrations of LMB-12, LMB-100, or LMB-164 anti-MSLN targeted RITs for 72 hours before WST-8 assay of cell viability.
In Vitro Model	Pancreatic ductal adenocarcinoma	KLM-1 cells		CVCL_5146

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	G1LG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 110.00 ng/mL	Positive GPC3 expression (GPC3+++/++)
Method Description	Ten thousand cells were seeded in a 96-well cell culture plate (200 l per well), supplemented with purified immunotoxins at the indicated final concentrations, and incubated at 37°C for 3 days. Cell viability was determined by quantifying the enzymatic activity of the intracellular luciferase that was released by two rounds of freezing-thawing.    Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	G1LG cells		Homo sapiens

Ref 1	Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma. J Cancer. 2022 Feb 14;13(4):1370-1384.
Ref 2	Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma. J Cancer. 2022 Feb 14;13(4):1370-1384.
Ref 3	Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. Clin Colorectal Cancer. 2019 Sep;18(3):192-199.e1. doi: 10.1016/j.clcc.2019.06.006. Epub 2019 Jul 2.
Ref 4	In Vitro Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer. Anticancer Res. 2018 Jan;38(1):61-69. doi: 10.21873/anticanres.12192.
Ref 5	Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. Cancer Res. 2016 Mar 15;76(6):1560-8. doi: 10.1158/0008-5472.CAN-15-2401. Epub 2015 Dec 30.